Table 2.
Complement pathway activities and activation product levels at different time points before and after transplantation.
| Parameter | Before HSCT | Day 28 | Day 56 | Day 100 | P-value |
|---|---|---|---|---|---|
|
Classical pathway activity, CH50/ml Reference range: 48–103 |
|||||
| TA-TMA (n = 10) | 73 (56–95) | 90 (74–110) | 87 (77–106) | 88 (72–120) | ns |
| No TA-TMA (n = 57) | 70 (63–96) | 77 (69–100) | 79 (66–92) | 72 (61–84) | |
|
Alternative pathway activity, % Reference range: 70–125 |
|||||
| TA-TMA (n = 10) | 87 (75–106) | 105 (42–119) | 92 (80–102) | 106 (99–109) | ns |
| No TA-TMA (n = 57) | 89 (69–107) | 94 (72–109) | 92 (63–102) | 89 (70–99) | |
|
MBL pathway activity, % Reference range: 35–130 |
|||||
| TA-TMA (n = 10) | 117 (80–119) | 115 (62–118) | 105 (102–128) | 122 (90–126) | ns |
| No TA-TMA (n = 57) | 84 (18–145) | 105 (20–150) | 99 (12–162) | 95 (21–120) | |
|
Complement C3, g/L Reference range: 0.9–1.8 |
|||||
| TA-TMA (n = 10) | 1.42 (1.26–1.44) | 1.51 (0.95–1.79) | 1.5 (1.28–1.96) | 1.43 (1.33–1.73) | ns |
| No TA-TMA (n = 57) | 1.35 (1.16–1.58) | 1.37 (1.2–1.64) | 1.31 (1.15–1.49) | 1.25 (1.06–1.36) | |
|
Complement C4, g/L Reference range: 0.15–0.55 |
|||||
| TA-TMA (n = 10) | 0.38 (0.29–0.44) | 0.38 (0.36–0.53) | 0.45 (0.36–0.5) | 0.5 (0.42–0.56) | 0.009 for TA-TMA |
| No TA-TMA (n = 57) | 0.36 (0.26–0.45) | 0.39 (0.3–0.51) | 0.35 (0.27–0.43) | 0.33 (0.26–0.4) | |
|
FH, mg/L Reference range: 250-880 |
|||||
| TA-TMA (n = 10) | 690 (456–758) | 564 (440–715) | 479(369–897) | 535 (419–761) | ns |
| No TA-TMA (n = 57) | 448 (316–605) | 468 (347–612) | 449 (296–614) | 444 (313.9–531) | |
|
FI, % Reference range: 70–130 |
|||||
| TA-TMA (n = 10) | 90 (83–102) | 76 (73–83) | 79 (70–89) | 77 (72–94) | ns |
| No TA-TMA (n = 57) | 88 (78–102) | 86 (76–103) | 88 (76–105) | 81 (70–97) | |
|
FB, % Reference range: 70–130 |
|||||
| TA-TMA (n = 10) | 98 (89–102) | 89 (85–102) | 106 (67–122) | 84 (74–98) | ns |
| No TA-TMA (n = 57) | 90 (74–102) | 84 (67–110) | 82 (67–100) | 85 (68–104) | |
|
ADAMTS13 activity, % Reference range: 67–151 |
|||||
| TA-TMA (n = 10) | 99 (81–116) | 68 (60–96) | 84 (65–117) | 92 (58–117) | ns |
| No TA-TMA (n = 57) | 91 (70–112) | 78 (55–102) | 93 (58–121) | 96 (62–120) | |
|
sC5b-9, ng/ml Reference range: 110–252 |
|||||
| TA-TMA (n = 10) | 157 (128–202) | 240 (219–376) | 210 (161–272) | 137 (126–148) | 0.003 for TA-TMA |
| No TA-TMA (n = 57) | 153 (113–220) | 164 (110–201) | 147 (120–189) | 149 (108–201) | |
|
C1q, mg/L Reference range: 60–180 |
|||||
| TA-TMA (n = 10) | 90.9 (77.9-112) | 101.6 (63-116.1) | 102.6 (90-120) | 93.1 (35-125.7) | ns |
| No TA-TMA (n = 57) | 89.9 (73.2–105.5) | 78.1 (68.5–95.5) | 78.7 (64.2–91.1) | 66.3 (50.7–84.8) |
Data are presented as median (interquartile range). P-values were obtained with two-way analysis of variance.
ns, not significant.